Posaconazole for invasive aspergillosis? [1]

Clinical Infectious Diseases

Volumn 45, Issue 5, 2007, Pages 664-

  Baden, Lindsey R ^a   Marty, Francisco M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POSACONAZOLE; VORICONAZOLE;

ASPERGILLOSIS; DRUG RESEARCH; HUMAN; LETTER; MORTALITY; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; CASE-CONTROL STUDIES; HUMANS; REPRODUCIBILITY OF RESULTS; SALVAGE THERAPY; SELECTION BIAS; TRIAZOLES;

EID: 34548246011     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/519510     Document Type: Letter

References (6)

1. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44:2-12.
2. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven, 1998.
3. Bennett JE. Salvage therapy for aspergillosis. Clin Infect Dis 2005; 41(Suppl 6):S387-8.
4. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for industry: E 10 choice of control group and related issues in clinical trials. Section 2.5.4. Available at: http://www.fda.gov/Cder/guidance/ 4155fnl.htm#P612_91126. Accessed 24 March 2007.
5. Baden LR, Katz JT, Fishman JA, et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 2003; 76:1632-7.
6. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis - has the principle been proven? N Engl J Med 2007; 356:409-11.